Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Seagate Technology Holdings PLC (STX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Seagate Technology Holdings PLC — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $300.86 (market cap $8.04B), while Seagate Technology Holdings PLC trades at $822.55 (market cap $198.72B). The key difference: Seagate Technology Holdings PLC is far larger — about 24.7× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Seagate Technology Holdings PLC pays a 0.34% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | STX | |
|---|---|---|
Market Cap | $8.04B | $198.72B |
Sector | Health | Technology |
52-Week High | $339.75 | $1.09K |
52-Week Low | $241.71 | $146.59 |
Enterprise Value | $7.85B | $201.75B |
Dividend Yield | — | 0.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
STX trades at $860.66, down 5.46% over 24 hours, with a bearish technical signal and elevated valuation ratios (P/E 81.66, P/S 17.61). Recent earnings beats (Q1 2026 EPS $4.10 vs. $3.51 expected) and strong revenue growth to $9.10B in 2025 highlight operational momentum, though negative shareholder equity and high debt pose balance sheet concerns. Analyst consensus remains bullish with a $987.86 price target, supported by AI-driven storage demand upgrades from Wells Fargo on July 10, 2026.
Outlook: STX benefits from AI infrastructure tailwinds and earnings consistency, but high leverage and volatile cash flows present risks. The stock offers upside to analyst targets if execution continues, yet investors face sensitivity to memory market cycles and debt servicing challenges amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Seagate Technology Holdings PLC
Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →
